New directions in Europe’s evolving ecosystem

Oncology’s development playbook is changing. Learn more about these changes in development model trends, European regulatory requirements, and biomarker-driven strategies, with insights from Pharma Ignite and Kadans Science Partner.

Explore this new focus on earlier-stage oncology development as it coincides with Europe’s In Vitro Diagnostic Regulation (IVDR).

Read the white paper to learn more about:

Overcoming limitations of traditional development: emerging earlier-stage development models
Leveraging integrated oncology development ecosystems
Navigating Europe’s IVDR and new biomarker validation requirements
Incorporating patient perspectives into development strategy
Engaging in early and substantive regulatory collaboration
Driving innovation and value with pan-European, integrated platforms and collaborative partnerships

Register for the White paper

Your Company Email Address

Opt In?

By completing this form you agree Kadans Science Partner and Citeline may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Kadans Science Partner and Citeline.